Logo of Anteris Technologies Global (ASX:AVR)Latest Anteris Technologies Global (ASX:AVR) News

Page 1
Page 1 of 3

Healthcare Wrap - Week 46 (9 Nov -> 13 Nov) 2026

EBR’s WiSE rollout slowed sharply as debt worries hit the stock, while Biome gained on a planned China launch.
Across aged care and healthcare technology, investors weighed stronger revenue against cash needs, trial delays and regulatory hurdles.
Logan Eniac
14 Nov 2026

Anteris burns US$22.9M as DurAVR trial and manufacturing scale-up gather pace

Anteris Technologies reported a wider third-quarter loss as spending accelerated on its PARADIGM heart-valve trial and manufacturing expansion. The company ended September with US$236.3 million in cash, but also retained unresolved weaknesses in financial reporting controls.
Ada Torres
11 Nov 2026

Healthcare Wrap - Week 33 (10 Aug -> 14 Aug) 2026

Healthcare shares delivered mixed results as Percheron surged on a leadership change, while ResMed gained on stronger sales and portfolio changes.
Biotech funding, medical-device expansion and new software contracts shaped the week, but several small-cap gaps quickly lost ground.
Logan Eniac
15 Aug 2026

Anteris Reports $51.7M Loss, Advances DurAVR Trial with $320M Capital Raise

Anteris Technologies posted a $51.7 million loss in H1 2026 amid ramped-up R&D and clinical trial activity, supported by a $320 million capital raise and Medicare reimbursement for its DurAVR heart valve trial.
Ada Torres
12 Aug 2026

Healthcare Wrap - Week 22 (25 May -> 29 May) 2026

Biotech names led healthcare trading this week, with Noxopharm, Acrux and TruScreen posting the biggest moves after clinical, licensing and expansion updates. Stronger cash flow, fresh capital and new contracts also lifted sentiment across medtech, aged care and healthcare services.
Logan Eniac
30 May 2026

Anteris Technologies Launches $250M ATM Stock Offering to Fund DurAVR Development

Anteris Technologies Global Corp. has initiated an at-the-market equity offering to raise up to US$250 million, aiming to accelerate development of its DurAVR transcatheter heart valve and support general corporate needs.
Ada Torres
25 May 2026

Anteris Raises $320M, Advances DurAVR Trial with US Enrollment

Anteris Technologies reported a $22.9 million net loss in Q1 2026 but bolstered its cash position to $283 million following a $320 million capital raise. The company is scaling manufacturing and clinical activities for its DurAVR transcatheter heart valve, with US patient enrolment now underway in the pivotal PARADIGM Trial.
Ada Torres
13 May 2026

Healthcare Wrap - Week 19 (4 May -> 8 May) 2026

Big capital raisings, fresh trial data and a few boardroom shocks shaped healthcare trading this week. The biggest moves came from companies either fixing the balance sheet, explaining heavy selling, or pushing key drugs and devices closer to market.
Logan Eniac
9 May 2026

Anteris Enrolls First US Patients in Pivotal DurAVR Heart Valve Trial

Anteris Technologies has treated the first US patients in its global PARADIGM trial, marking a key milestone in testing its DurAVR transcatheter heart valve against established devices.
Ada Torres
6 May 2026

Healthcare Wrap - Week 18 (27 Apr -> 1 May) 2026

Biotech price swings were led by Dimerix’s slide, while TrivarX and LTR Pharma surged on clinical and commercial progress. Capital raisings, FDA milestones and first sales kept healthcare investors busy, but several early jumps faded as traders locked in gains.
Logan Eniac
2 May 2026

Anteris Secures Medicare Reimbursement to Boost US PARADIGM Trial Activation

Anteris Technologies has gained U.S. Medicare reimbursement eligibility for its pivotal PARADIGM Trial, clearing a key hurdle for clinical site activation and accelerating its transcatheter heart valve study.
Ada Torres
28 Apr 2026

Healthcare Wrap - Week 9 (23 Feb -> 27 Feb) 2026

Cannabis and psychedelics delivered the week’s biggest winner, while a cluster of smaller caps slid on fresh losses, leadership change, and near-term uncertainty. Investors kept paying up for FDA clearances and reimbursement wins, but punished businesses where early pops quickly disappeared.
Logan Eniac
28 Feb 2026